Feasibility of Using Serum, Plasma, and Platelet 5-hydroxytryptamine as Peripheral Biomarker for the Depression Diagnosis and Response Evaluation to Antidepressants: Animal Experimental Study

키워드

참고문헌 (54)

1. "Depressive disorder (depression)" (2023)[URL]
2. Harsanyi S, "Selected biomarkers of depression : what are the effects of cytokines and inflammation?", Int J Mol Sci, 24, pp.578~ (2022)
3. Jesulola E, "Understanding the pathophysiology of depression : from monoamines to the neurogenesis hypothesis model-are we there yet?", Behav Brain Res, 341, pp.79~90 (2018)
4. Tsai TY, "The interaction of oxytocin and social support, loneliness, and cortisol level in major depression", Clin Psychopharmacol Neurosci, 17, pp.487~494 (2019)
5. Eun TK, "Association between the 5-HTTLPR genotype and childhood characteristics in mood disorders", Clin Psychopharmacol Neurosci, 14, pp.88~95 (2016)
6. Coppen A, "The biochemistry of affective disorders", Br J Psychiatry, 113, pp.1237~1264 (1967)
7. Albert PR, "The neurobiology of depression--revisiting the serotonin hypothesis. I. Cellular and molecular mechanisms", Philos Trans R Soc Lond B Biol Sci, 367, pp.2378~2381 (2012)
8. Hahn A, "Attenuated serotonin transporter association between dorsal raphe and ventral striatum in major depression", Hum Brain Mapp, 35, pp.3857~3866 (2014)
9. Yohn CN, "The role of 5-HT receptors in depression", Mol Brain, 10, pp.28~ (2017)
10. Meyer JH, "Imaging the serotonin transporter during major depressive disorder and antidepressant treatment", J Psychiatry Neurosci, 32, pp.86~102 (2007)
11. Smith K, "Mental health : a world of depression", Nature, 515, pp.181~ (2014)
12. Malik S, "Biomarkers of major depressive disorder : knowing is half the battle", Clin Psychopharmacol Neurosci, 19, pp.12~25 (2021)
13. Ogawa S, "Cerebrospinal fluid monoamine metabolite concentrations in depressive disorder : a meta-analysis of historic evidence", J Psychiatr Res, 105, pp.137~146 (2018)
14. Sarrias MJ, "Decreased plasma serotonin in melancholic patients : a study with clomipramine", Biol Psychiatry, 22, pp.1429~1438 (1987)
15. Choi W, "Interaction effect of serum serotonin level and age on the 12-week pharmacotherapeutic response in patients with depressive disorders", Sci Rep, 11, pp.24226~ (2021)
16. Mück-Seler D, "The effects of paroxetine and tianeptine on peripheral biochemical markers in major depression", Prog Neuropsychopharmacol Biol Psychiatry, 26, pp.1235~1243 (2002)
17. Liu MY, "Pretreatment with ginseng fruit saponins affects serotonin expression in an experimental comorbidity model of myocardial infarction and depression", Aging Dis, 7, pp.680~686 (2016)
18. Kudryashov NV, "The behavioral and neurochemical aspects of the interaction between antidepressants and unpredictable chronic mild stress", Acta Naturae, 12, pp.63~72 (2020)
19. Li C, "Could peripheral 5-HT level be used as a biomarker for depression diagnosis and treatment? A narrative minireview", Front Pharmacol, 14, pp.1149511~ (2023)
20. Yang Z, "Antitumor effect of fluoxetine on chronic stress-promoted lung cancer growth via suppressing kynurenine pathway and enhancing cellular immunity", Front Pharmacol, 12, pp.685898~ (2021)
21. Li G, "Effects of EGCG on depression-related behavior and serotonin concentration in a rat model of chronic unpredictable mild stress", Food Funct, 11, pp.8780~8787 (2020)
22. Moncrieff J, "The serotonin theory of depression : a systematic umbrella review of the evidence", Mol Psychiatry, 28, pp.3243~3256 (2023)
23. Nollet M, "Models of depression : unpredictable chronic mild stress in mice", Curr Protoc, 1, pp.e208~ (2021)
24. Wang LS, "LC-MS", MS-based quantification of tryptophan metabolites and neurotransmitters in the serum and brain of mice, 2019, pp.1112, 24~32
25. Willner P, "The chronic mild stress(CMS)model of depression : history, evaluation and usage", Neurobiol Stress, 6, pp.78~93 (2016)
26. Antoniuk S, "Chronic unpredictable mild stress for modeling depression in rodents : meta-analysis of model reliability", Neurosci Biobehav Rev, 99, pp.101~116 (2019)
27. Ferrari AJ, "Global variation in the prevalence and incidence of major depressive disorder : a systematic review of the epidemiological literature", Psychol Med, 43, pp.471~481 (2013)
28. Lindström M, "Comparison of serum serotonin and serum 5-HIAA LC-MS", MS assays in the diagnosis of serotonin producing neuroendocrine neoplasms : a pilot study, 2018, pp.482, 78~83
29. Sorge RE, "Different immune cells mediate mechanical pain hypersensitivity in male and female mice", Nat Neurosci, 18, pp.1081~1083 (2015)
30. Audhya T, "Correlation of serotonin levels in CSF, platelets, plasma, and urine", Biochim Biophys Acta, 1820, pp.1496~1501 (2012)
31. Fajardo O, "Serotonin, serotonin 5-HT1A receptors and dopamine in blood peripheral lymphocytes of major depression patients", Int Immunopharmacol, 3, pp.1345~1352 (2003)
32. Matthes S, "Peripheral serotonin synthesis as a new drug target", Trends Pharmacol Sci, 39, pp.560~572 (2018)
33. Scotton WJ, "Serotonin syndrome : pathophysiology, clinical features, management, and potential future directions", Int J Tryptophan Res, 12, pp.1178646919873925~ (2019)
34. Fakhoury M, "New insights into the neurobiological mechanisms of major depressive disorders", Gen Hosp Psychiatry, 37, pp.172~177 (2015)
35. Bianchi M, "Forced swimming test and fluoxetine treatment : in vivo evidence that peripheral 5-HT in rat platelet-rich plasma mirrors cerebral extracellular 5-HT levels, whilst 5-HT in isolated platelets mirrors neuronal 5-HT changes", Exp Brain Res, 143, pp.191~197 (2002)
36. Fakhoury M, "Revisiting the serotonin hypothesis : implications for major depressive disorders", Mol Neurobiol, 53, pp.2778~2786 (2016)
37. Anderson GM, "Determination of serotonin in whole blood, platelet-rich plasma, platelet-poor plasma and plasma ultrafiltrate", Life Sci, 40, pp.1063~1070 (1987)
38. Birkenhäger TK, "Lithium addition in antidepressantresistant depression : effects on platelet 5-HT, plasma 5-HT and plasma 5-HIAA concentration", Prog Neuropsychopharmacol Biol Psychiatry, 31, pp.1084~1088 (2007)
39. Brand T, "The measurement of platelet-poor plasma serotonin : a systematic review of prior reports and recommendations for improved analysis", Clin Chem, 57, pp.1376~1386 (2011)
40. Todrick A, "Blood platelet 5-hydroxytryptamine levels in psychiatric patients", J Ment Sci, 106, pp.884~890 (1960)
41. Boullin DJ, "Abnormalities in platelet 5-hydroxytryptamine efflux in patients with infantile autism", Nature, 226, pp.371~372 (1970)
42. Boullin DJ, "Accumulation of dopamine by blood platelets from normal subjects and parkinsonian patients under treatment with L-DOPA", Br J Pharmacol, 39, pp.779~788 (1970)
43. Karatoprak S, "Neutrophillymphocyte and platelet-lymphocyte ratios among adolescents with substance use disorder : a preliminary study", Clin Psychopharmacol Neurosci, 19, pp.669~676 (2021)
44. Cıcek E, "Increased neutrophil-lymphocyte and platelet-lymphocyte ratios in male heroin addicts : a prospective controlled study", Clin Psychopharmacol Neurosci, 16, pp.190~196 (2018)
45. Musselman DL, "Exaggerated platelet reactivity in major depression", Am J Psychiatry, 153, pp.1313~1317 (1996)
46. Lima L, "Allelic isoforms and decrease in serotonin transporter mRNA in lymphocytes of patients with major depression", Neuroimmunomodulation, 12, pp.299~306 (2005)
47. Franke L, "Serotonergic platelet variables in unmedicated patients suffering from major depression and healthy subjects : relationship between 5HT content and 5HT uptake", Life Sci, 67, pp.301~315 (2000)
48. Schneider MA, "Attenuation of peripheral serotonin inhibits tumor growth and enhances immune checkpoint blockade therapy in murine tumor models", Sci Transl Med, 13, pp.eabc8188~ (2021)
49. Li X, "Decreased platelet 5-hydroxytryptamin(5-HT)levels : a response to antidepressants", J Affect Disord, 187, pp.84~90 (2015)
50. Alvarez JC, "Plasma serotonin level after 1 day of fluoxetine treatment : a biological predictor for antidepressant response?", Psychopharmacology(Berl), 143, pp.97~101 (1999)
51. Biomarkers Definitions Working Group, "Biomarkers and surrogate endpoints : preferred definitions and conceptual framework", Clin Pharmacol Ther, 69, pp.89~95 (2001)
52. Cagney DN, "The FDA NIH Biomarkers, EndpointS, and other Tools(BEST)resource in neuro-oncology", Neuro Oncol, 20, pp.1162~1172 (2018)
53. Gafarov VV, "Arterial hypertension, myocardial infarction and stroke : risk of development and psychosocial factors", Alaska Med, 49(2 Suppl), pp.117~119 (2007)
54. Gabriele S, "Blood serotonin levels in autism spectrum disorder : a systematic review and meta-analysis", Eur Neuropsychopharmacol, 24, pp.919~929 (2014)

관련 논문AI추천